The pharmaceutical industry in developed countries spends 10%~20% of its sales on the research and development of new drugs, and it costs more than 200-300 million dollars to successfully develop a new chemically synthesized drug. In 2003, the total output value of China pharmaceutical industry was 654.38+02 billion RMB, which was not as good as the annual output value of international pharmaceutical giant Merck. However, in recent years, the R&D investment of the whole pharmaceutical industry in China only hovered around 654.38+0% of the total sales.
Development status:
The overall innovation ability of pharmaceutical enterprises is limited. Innovation is the lifeline of pharmaceutical industry. The innovation power of the pharmaceutical industry mainly comes from two aspects: first, human health is constantly threatened by various new diseases, and the pharmaceutical industry must constantly expand its own development fields; Second, the variation of bacteria and viruses reduces the curative effect of traditional drugs, and urges human beings to speed up the pace of drug upgrading.
The pharmaceutical industry is also an industry with high investment, high return and high risk. Because the pharmaceutical industry has been facing great pressure of continuous innovation, pharmaceutical companies must increase their research and development efforts.